Editorial: Immunotherapy in Multiple Myeloma

Front Immunol. 2019 Aug 14:10:1945. doi: 10.3389/fimmu.2019.01945. eCollection 2019.

Authors

Nicola Giuliani^{1

2}, Fabio Malavasi³

Affiliations

¹ Department of Medicine and Surgery, University of Parma, Parma, Italy.
² U.O. di Ematologia e Centro Trapianti Midollo Osseo, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
³ Department of Medical Science, University of Turin and "Fondazione Ricerca Molinette", Turin, Italy.

No abstract available

Keywords: CD38; immune checkpoints; immunotherapy; monoclonal Ab; multiple myeloma.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

ADP-ribosyl Cyclase 1 / antagonists & inhibitors
ADP-ribosyl Cyclase 1 / immunology
ADP-ribosyl Cyclase 1 / metabolism
Antibodies, Monoclonal / immunology
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / immunology
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / therapeutic use
Bortezomib / therapeutic use
Humans
Immunotherapy / methods*
Immunotherapy / trends
Melphalan / therapeutic use
Multiple Myeloma / immunology
Multiple Myeloma / therapy*
Signaling Lymphocytic Activation Molecule Family / antagonists & inhibitors
Signaling Lymphocytic Activation Molecule Family / immunology
Signaling Lymphocytic Activation Molecule Family / metabolism
Thalidomide / therapeutic use

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
SLAMF7 protein, human
Signaling Lymphocytic Activation Molecule Family
elotuzumab
daratumumab
Thalidomide
Bortezomib
ADP-ribosyl Cyclase 1
Melphalan